Table 1 Demographic characteristics of the participants (FAS)

From: Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

 

NVSI-06-09 (N = 260)

BBIBP-CorV (N = 256)

p value

Age (years)

 Mean (SD)

37.2 (9.1)

37.3 (8.7)

0.8740

 Median

36.0

36.5

 

 Min, Max

19, 62

19, 63

 

Sex, n (%)

  

0.4622

 Male

244 (93.85)

244 (95.31)

 

 Female

16 (6.15)

12 (4.69)

 

Race, n (%)

  

0.4216

 Chinese

0 (0.00)

0 (0.00)

 

 Asian (except Chinese)

243 (93.46)

242 (94.53)

 

 Black/African/Caribbean

6 (2.31)

8 (3.13)

 

 White

11 (4.23)

6 (2.34)

 

 Multiracial

0 (0.00)

0 (0.00)

 

 Other

0 (0.00)

0 (0.00)

 

Body temperature before immunization (°C)

 Mean (SD)

36.41 (0.19)

36.42 (0.20)

0.5994

 Median

36.40

36.40

 

 Min, Max

36.0, 37.0

36.1, 37.0

 

Height (cm)

 Mean (SD)

171.2 (7.2)

170.9 (7.3)

0.5493

 Median

171.0

171.0

 

 Min, Max

151, 195

146, 192

 

Weight (kg)

 Mean (SD)

78.69 (14.52)

80.96 (14.34)

0.0745

 Median

79.00

79.00

 

 Min, Max

49.0, 131.0

49.0, 136.0

 

Cardiopulmonary auscultation, n (%)

  

1.0000

 Normal

260 (100.00)

256 (100.00)

 

 Abnormal

0 (0.00)

0 (0.00)

 

PCR test before immunization, n (%)

  

0.8935

 Negative

236 (90.77)

233 (91.02)

 

 Positive

11 (4.23)

9 (3.52)

 

 Weak positive

13 (5.00)

14 (5.47)

 

Time between last primary vaccination and baseline sample (day)

Median (IQR)

259 (236–279)

264 (237–284)

0.0926

  1. The p value for comparing the NVSI-06-09 and BBIBP-CorV groups was calculated by using two-sided student’s t-test (or rank sum test) for continuous data (after log-transformation of antibodies) and two-sided Chi-square test for non-ordered categorical data
  2. n = participant number
  3. SD standard deviation, PCR polymerase chain reaction, IQR interquartile range
Back to article page